Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I dont think there is anything to buy except debt and lawsuits
Because I felt the same way. A lot of products on the shelves, but mismanagement did not let it go anywhere. Maybe it's time for someone to look into buying the company?
Managment were scam artists. Had a great product but they were too incompetent to do anything. Why do u ask?
Yep has been
Wow--nothing new here in days!!!!
I used to see some at a Food Lion, but they don't carry any of their products anymore. I don't think anyone ever bought them.
Are TRAB's products still on the shelves?
I doubt it will have any effect. Long term, I expect this to drift down.
So do you think it's going to move up?
Normal...officially a pink now.
TRAB got the E removed???
Is something go to happen? Will it run?
What I heard is Kelly is and his other partners in UEEC.
Especially with the Big Pharma Giant PR. They should be investigated for that.
This stock was a scam......
How did Kelley sign the 11/5/12 8K if he resigned as of 10/12/12?
The nail in the coffin!!!!!!
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 12, 2012
Date of Report (Date of earliest event reported)
THERABIOGEN, INC.
(Exact name of registrant as specified in its charter)
Nevada
000-53008
98-0559606
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
P.O. Box 296, Manalapan, New Jersey
07726
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Section 5 - Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers
Effective October 12, 2012, Kelly T. Hickel, our Chairman and CEO, resigned as an officer, director and employee of the Company for personal reasons. Mr. Hickel has not provided us with any written statement concerning his resignation that contains any disagreement or difference with the company on any matter of policy or operations and has not expressed any such concerns to us. By copy of this filing sent to Mr. Hickel, we advised him of the disclosures being made in this Current Report and provided him with an opportunity to furnish us with a letter starting whether he agrees or disagrees with the disclosures and if he disagrees, stating the reasons for such disagreement. A copy of the letter from Mr. Hickel dated November 14, 2012 stating that he agrees with the disclosures in this Current Report is attached as an exhibit to this Current Report.
Section 8 – Other Events
Item 8.01 – Other Events
On November 9, 2012, we were advised that a creditor of the Company has completed its foreclosure of the Company’s assets, including the license to manufacture, market and sell the TheraMax ™ homeopathic cold and flu products which have been distributed by the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
November 15, 2012
THERABIOGEN, INC.
By: Board of Directors
Looks like something going on with this stock.
When and how high do you predict?
Still is worth something.... It's going to go back up again...
That's too bad, those products they had were worth something.
Any chance of this stock moving....???
Its past that bravo. Best bet is they have a clean shell for sell. This is done
Time to re-assemble this company..
8-K out. It's over and they destroyed this company. Really sad
Current Report Filing (8-k)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 5, 2012
Date of Report (Date of earliest event reported)
THERABIOGEN, INC.
(Exact name of registrant as specified in its charter)
Nevada
000-53008
98-0559606
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
P.O. Box 296, Manalapan, New Jersey
07726
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Section 1 - Registrant’s Business and Operations
Item 1.02 Termination of a Material Definitive Agreement
Effective October 8, 2012, DBI, LLC terminated a consulting agreement with us dated May 23, 2012, pursuant to which DBI’s principal, Dean Blechman, had provided consulting marketing services to us.
Section 2 – Financial Information
Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement.
As previously disclosed, we are a party to a financing agreement with our principal lender, which holds a first priority security interest in our assets. Due to our financial circumstances, we have been unable to pay our lender amounts due under a $250,000 line of credit used for the financing of inventory purchases, plus certain related fees, as well as accrued interest on the line of credit, and the lender has declared us in default of these obligations. We also have been unable to secure alternate financing to retire the amounts due. We are now advised that the lender has initiated steps to foreclose on its security interest in our assets and that a foreclosure sale will be held on November 8, 2012. Unless this foreclosure and sale in postponed or alternative arrangements can be made, we will be without any operating assets as a result, and will no longer be able to engage in any business activity or pay our debts. While the Board of Directors has discussed the possibility of filing a Chapter 11 bankruptcy proceeding, or lack of any cash or other resources needed to retain a bankruptcy attorney to commence and maintain such an action has precluded this option.
Section 5 - Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers
Effective October 25, 2012, one of our Directors, Thomas E. Kelly resigned from his position as Director for personal reasons. Mr. Kelly has not provided us with any written statement concerning his resignation that contains any disagreement or difference with the company on any matter of policy or operations and has not expressed any such concerns to us. By copy of this filing sent to Mr. Kelly, we are advising him of the disclosures being made in this Current Report and are providing him with an opportunity to furnish us with a letter starting whether he agrees or disagrees with the disclosures and if he disagrees, stating the reasons for such disagreement. In the event that Mr. Kelly provides us with such a letter, we will file a copy of the letter as an exhibit to an amendment to this Current Report.
Section 8 – Other Events
Item 8.01 – Other Events
We currently lack sufficient resources to engage attorneys or accountants in order to prepare and file the periodic reports required under the Securities Exchange Act of 1934, as amended. Our quarterly report for the period ended August 31, 2012 was not filed, and at this time, we have no
expectation of filing that report, or any subsequent quarterly or annual report, in the immediately foreseeable future. As a result of the failure to file the quarterly report for the period ended August 31, 2012, our trading symbol on the OTC BB has been change to TRABE, to signify the delinquency, and unless we file the report in the near future, our listing on the OTC BB will be terminated. In that event, our shares will only be traded on the OTCPink trading market, which will make it more difficult to trade our shares. We do not expect to file the quarterly report in time to prevent this result.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THERABIOGEN, INC.
Date: November 5, 2012
By:
/s/ Kelly T. Hickel
Kelly T. Hickel
Chief Executive Officer
Party over Dean is gone
Is this stock going to move....
I need to make back money......
b/c they cant pay for the filings... This deal is toast! not one capable person in the deal that can raise a dime, such a shame. NEXT!
TRAB got the "E" again?
Anyone knows why?
This stock blows....
Everyone that got this stock (me included) got f$&cked....
Looks like..
we are phucked.
Is every going to move or are we stuck???? Info please....
Chris Messalas (cm)
What's up with Therabiogen's website? Anyone know?
theramaxrelief.com
I think this is getting ready for another run.
Get ready for the E/delisting!!!!
get ready to join the shelf of CM retard molested shells such as SCRK BICB etc etc... When fools like Harj Manhas are involved get ready to short!!!
Harj's Next endevour is FCPS, he hopes to fool others into buying a non paid for shell like TRAB was to him and scrk...
These guys are so pathetic!!! move on, they will keep trying, but have no idea the world is watching....
Nor do they care....
Thats a big deal to this dip sh#t crew!!!! They are actually depending on Vince to bail them out!!!! HAHAHAHAAHA
can u say tomorrow!!!! meeting tomorrow!!!!!
YEAH!!!!!
AWESOME!!!!
KZP!
I thought CM was for Chris?
What's CM stand for?
apparently i mistook the reference of cm for chris messalas.
For 5 minutes and traded 1000 bucks worth of stock. Big deal
You must be the most informed and all around nice person on this site.
It's a pleasure to text talk with you.
Awww ..you're just saying that.
Good to know...
You are a very smart person!!!!!!
Followers
|
34
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1722
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
Under an exclusive world-wide licensing agreement with Nasal Therapeutics, Inc. ("NTI"), we have the right to develop, manufacture, market and
sell four homeopathic nasal sprays, THERA MAX® Cold Relief, THERA MAX® Flu Relief, THERA MAX® Allergy Relief and THERA
MAX® Migraine Relief. The Cold Relief and Flu Relief formulas are now marketed as a single product, THERA MAX® Cold and Flu Relief.
The principal of NTI, Dr. Charles Hensley also developed the homeopathic nasal product ZICAM®.
LATEST FINANCIAL RESULTS:
Three months ended November 30, 2011 versus three months ended November 30, 2010
We generated sales during the three months ended November 30, 2011 of approximately $693,000. Gross sales were approximately $1,180,000
reduced by discounts and allowances of approximately $487,000. During the period a major drug retailer conducted a national promotion of Thera
Max® in all of their retail outlets.
SEC: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001405286&owner=exclude&count=40
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |